Newron's Parkinson's Drug Xadago Has Narrower Indication Than Teva's Azilect
Executive Summary
After overcoming regulatory hurdles, Newron may have tough time competing in US against market stalwart Azilect; eight Parkinson's drugs are in Phase III trials.